Ozcan, Sevil published the artcileOxadiazole-isopropylamides as Potent and Noncovalent Proteasome Inhibitors, Synthetic Route of 163839-73-4, the publication is Journal of Medicinal Chemistry (2013), 56(10), 3783-3805, database is CAplus and MEDLINE.
Screening of the 50 000 ChemBridge compound library led to the identification of the oxadiazole-isopropylamide I (PI-1833) which inhibited chymotrypsin-like (CT-L) activity (IC50 = 0.60 ¦ÌM) with little effects on the other two major proteasome proteolytic activities, trypsin-like (T-L) and postglutamyl-peptide-hydrolysis-like (PGPH-L). LC-MS/MS and dialysis show that I is a noncovalent and rapidly reversible CT-L inhibitor. Focused library synthesis provided II (PI-1840) with CT-L activity (IC50 = 27 nM). Detailed SAR studies indicate that the amide moiety and the two Ph rings are sensitive toward modifications. Hydrophobic residues, such as Pr or Bu in the para position (not ortho or meta) of the A-ring and a m-pyridyl group as B-ring, significantly improve activity. Compound II (IC50 = 0.37 ¦ÌM) is more potent than I (IC50 = 3.5 ¦ÌM) at inhibiting CT-L activity in intact MDA-MB-468 human breast cancer cells and inhibiting their survival. The activity of II warrants further preclin. investigation of this class as noncovalent proteasome inhibitors.
Journal of Medicinal Chemistry published new progress about 163839-73-4. 163839-73-4 belongs to catalysis-chemistry, auxiliary class Trifluoromethyl,Fluoride,Carboxylic acid,Benzene,Ether, name is 2-(4-(Trifluoromethyl)phenoxy)acetic acid, and the molecular formula is C9H7F3O3, Synthetic Route of 163839-73-4.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia